Trabectedin-Irinotecan Combination Shows Promise Against EWS::FLI1 Fusion in Ewing Sarcoma Phase 1/2 Trial
核心洞察
A phase 1/2 trial published in Nature Medicine demonstrates that trabectedin combined with low-dose irinotecan can target the previously "undruggable" EWS::FLI1 (搜索) fusion protein found in 85% of Ewing sarcoma (搜索) cases.
The combination works through an indirect mechanism where trabectedin disrupts EWS::FLI1 (搜索) transcriptional activity by interfering with its DNA-binding program, while irinotecan provides complementary topoisomerase I (搜索) inhibition.
This trial represents a breakthrough in precision oncology for rare cancers, using a seamless adaptive phase 1/2 design to overcome the challenge of enrolling patients in a disease with only 200-300 new U.S. diagnoses annually.
A phase 1/2 clinical trial targeting the EWS::FLI1 (搜索) fusion protein in Ewing sarcoma (搜索) has demonstrated that a previously "undruggable" oncogenic driver can be effectively targeted through an innovative combination therapy approach. The study, published in Nature Medicine in 2026, combines trabectedin with low-dose irinotecan to disrupt the transcriptional program of EWS::FLI1, a fusion protein present in approximately 85% of Ewing sarcoma cases.
Targeting the "Undruggable" Fusion Protein
EWS::FLI1 (搜索) arises from a translocation between chromosomes 22 and 11, fusing the EWSR1 (搜索) gene to FLI1 (搜索), a transcription factor in the ETS family. Because transcription factors lack the enzymatic binding pockets that small molecules typically exploit, targeting EWS::FLI1 directly has historically been considered impossible. The trabectedin-irinotecan combination takes an indirect approach: trabectedin, a DNA minor groove binder originally derived from the sea squirt Ecteinascidia turbinata and approved in the United States and Europe for soft tissue sarcoma and ovarian cancer, disrupts EWS::FLI1 transcriptional activity by interfering with its DNA-binding program. Low-dose irinotecan adds topoisomerase I (搜索) inhibition as a complementary mechanism, targeting the transcriptional dependencies that EWS::FLI1 creates.
This mechanistic pairing represents a counterintuitive approach—attacking a transcription factor through its downstream DNA interactions rather than the protein directly. The phase 1/2 data validates this mechanistic reasoning with clinical signal, challenging the assumption that transcription factor fusions are regulatory targets rather than drug targets.
Innovative Trial Design for Rare Disease
The study's design addresses the unique challenges of conducting clinical trials in Ewing sarcoma (搜索), a disease so rare that enrolling 30 patients qualifies as a large study. With roughly 200 to 300 new diagnoses per year in the United States alone, the trial employed a seamless adaptive phase 1/2 structure that combines dose-finding and preliminary efficacy evaluation in a single protocol.
Patient stratification in this trial is binary in the most advantageous way possible. EWS::FLI1 (搜索) is either present or absent, with no ambiguous biomarker expression threshold or continuous variable requiring cut-point validation. The fusion is detected by RT-PCR or FISH with established methodology and is present in the overwhelming majority of Ewing sarcoma (搜索) diagnoses. This simplicity represents an operational advantage in a rare disease setting where enrollment windows are narrow and every screening failure compounds timeline risk.
Regulatory Implications for Precision Oncology
The trial's architecture serves as a practical case study in applying FDA's guidance on seamless adaptive trial designs to molecularly defined rare tumors. FDA's guidance on rare pediatric disease drug development acknowledges that "substantial evidence" in rare cancers may derive from smaller, mechanistically grounded datasets when the biology is well-characterized.
If the efficacy signal in the phase 2 expansion cohort maintains the magnitude suggested by the phase 1 safety and preliminary activity data, this trial could become a reference case for regulatory submissions under accelerated approval pathways. This would follow the single-arm, biomarker-selected submission architecture that FDA has accepted in other molecularly defined rare tumors, including the approvals granted to larotrectinib and entrectinib in NTRK (搜索) fusion-positive cancers.
Broader Impact on Fusion-Driven Programs
The success of this approach has implications extending well beyond Ewing sarcoma (搜索). Sponsors running fusion-driven rare tumor programs—including RET (搜索) fusions in thyroid cancer, FGFR (搜索) fusions in cholangiocarcinoma, and SS18::SSX fusions in synovial sarcoma—should examine this trial's methodology as operational precedent.
The trabectedin-irinotecan EWS::FLI1 (搜索) data now represents the most clinically advanced example of targeting transcription factor fusions therapeutically. If a biologics license application submission follows, the FDA's response to the efficacy evidence will define the regulatory framework for every transcription factor program in development.
The study was supported by funding from the National Institutes of Health/National Cancer Institute and Janssen Scientific Affairs (搜索), LLC, with additional support from multiple foundations including the V Foundation and the 1Million4Anna Foundation.